No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MYGN240517C25000
- 0.61
- -1.12-64.74%
15min DelayClose May 9 16:00 ET
0.61High0.61Low
0.61Open1.73Pre Close3 Volume10 Open Interest25.00Strike Price183.00Turnover43.06%IV2.18%PremiumMay 17, 2024Expiry Date0.25Intrinsic Value100Multiplier8DDays to Expiry0.36Time Value100Contract SizeAmericanOptions Type0.5808Delta0.2382Gamma31.56Leverage Ratio-0.0418Theta0.0032Rho18.33Eff Leverage0.0149Vega
Intraday
- 5D
- 1D
News
Myriad Genetics First Quarter 2024 Earnings: Beats Expectations
Investors Bid Myriad Genetics (NASDAQ:MYGN) up US$428m Despite Increasing Losses YoY, Taking One-year Return to 36%
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But you can significantly boost your returns by picking above-average stocks. To wit, the Myriad
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2024 Earnings Call Transcript
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks were slipping late Wednesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each easing around 0.3%. The iShares Biotechnology ETF (IBB
Myriad Genetics Price Target Raised to $35.00/Share From $25.00 by Leerink Partners
Myriad Genetics Price Target Raised to $35.00/Share From $25.00 by Leerink Partners
Myriad Genetics Raised to Outperform From Market Perform by Leerink Partners
Myriad Genetics Raised to Outperform From Market Perform by Leerink Partners
Comments
$Myriad Genetics(MYGN.US$ Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device 16 MINUTES AGO, 4:05 PM EDT VIA GLOBENEWSWIRE
1
14
The acquisition is expected to enable Myriad to more effectively scale and grow its tumor profiling offerings to complement its oncology portfolio of hereditary cancer and companion diagnostic testing options.
Dr. Daneker's leadership is expected to drive innovation, growth, and development of the company's oncology portfolio, including expansions into liquid biopsy and minimal residual disease testing. His experience and track record are anticipated to boost the company's strategy with health systems and large oncology practices.
The acquisition is set to spur innovation, growth, and further development of Myriad's oncology portfolio. It will also enhance the scaling and growth of their tumor profiling and liquid biopsy tests, including operational efficiencies, reimbursement benefits and new clinical development opportunities.
The low P/S ratio for Myriad Genetics is likely due to its subpar revenue performance and limited future growth expectations, which have suppressed its share price. These conditions could hinder a significant rise in the share price in the near future.
Read more
Jaguar8 : Yes it’s quite disappointing that people don’t realize the importance of this.
TrytosaveabitOP Jaguar8: Yup! I have a volume and price move alerts set! Hehehe
Jaguar8 TrytosaveabitOP: What volume do you usually set like 1M?
TrytosaveabitOP Jaguar8: 300K in 3 minutes
Jaguar8 TrytosaveabitOP: Wow that is fast volume
View more comments...